Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s share price gapped up prior to trading on Friday . The stock had previously closed at $43.31, but opened at $45.34. Apellis Pharmaceuticals shares last traded at $45.00, with a volume of 315,280 shares changing hands.
Analyst Upgrades and Downgrades
APLS has been the topic of a number of analyst reports. JPMorgan Chase & Co. lowered shares of Apellis Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $72.00 to $60.00 in a research report on Thursday, August 3rd. HC Wainwright reiterated a “buy” rating and set a $82.00 price objective on shares of Apellis Pharmaceuticals in a report on Thursday. Stifel Nicolaus raised their price target on shares of Apellis Pharmaceuticals from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, August 29th. Bank of America lifted their price objective on shares of Apellis Pharmaceuticals from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Friday, September 8th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Apellis Pharmaceuticals in a research note on Wednesday, August 23rd. Five investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $66.13.
View Our Latest Research Report on APLS
Apellis Pharmaceuticals Stock Up 2.6 %
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last announced its earnings results on Monday, July 31st. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.33. The firm had revenue of $95.00 million for the quarter, compared to analyst estimates of $70.38 million. Apellis Pharmaceuticals had a negative return on equity of 212.82% and a negative net margin of 356.02%. The business’s revenue was up 482.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.46) EPS. On average, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -4.89 EPS for the current year.
Insider Activity
In related news, CEO Cedric Francois sold 150,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $41.75, for a total transaction of $6,262,500.00. Following the completion of the sale, the chief executive officer now owns 424,655 shares in the company, valued at $17,729,346.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Apellis Pharmaceuticals news, CEO Cedric Francois sold 150,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $41.75, for a total value of $6,262,500.00. Following the completion of the sale, the chief executive officer now owns 424,655 shares in the company, valued at $17,729,346.25. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Alec Machiels sold 1,250 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The shares were sold at an average price of $88.41, for a total value of $110,512.50. Following the completion of the transaction, the director now directly owns 267,641 shares in the company, valued at approximately $23,662,140.81. The disclosure for this sale can be found here. In the last quarter, insiders sold 204,340 shares of company stock worth $9,665,314. 7.50% of the stock is currently owned by company insiders.
Institutional Trading of Apellis Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Clearstead Advisors LLC acquired a new stake in Apellis Pharmaceuticals during the first quarter worth about $27,000. National Bank of Canada FI acquired a new stake in shares of Apellis Pharmaceuticals in the second quarter valued at about $33,000. IFP Advisors Inc grew its stake in Apellis Pharmaceuticals by 49,525.0% during the 1st quarter. IFP Advisors Inc now owns 1,985 shares of the company’s stock valued at $39,000 after purchasing an additional 1,981 shares in the last quarter. Focused Wealth Management Inc acquired a new stake in Apellis Pharmaceuticals during the 2nd quarter valued at approximately $45,000. Finally, US Bancorp DE grew its stake in Apellis Pharmaceuticals by 391.2% during the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after purchasing an additional 884 shares in the last quarter. 90.43% of the stock is currently owned by hedge funds and other institutional investors.
About Apellis Pharmaceuticals
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).
Featured Articles
- Five stocks we like better than Apellis Pharmaceuticals
- Are Stock Buybacks Good for the Average Investor?
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- How to Invest in Grocery Stores
- MarketBeat Week in Review – 9/11 – 9/15
- How Investors Can Find the Best Cheap Dividend Stocks
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
